EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer

Lanxin Zhang, Huazhang Li, Siwen Sun, Ning Li, Shanshan Zhao, Zuowei Zhao, Man Li

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189649

DOI: 10.1016/j.bbcan.2026.189649 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Lanxin Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 135 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Dalian Medical University, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of trastuzumab, pertuzumab, and taxane (THP) has been the cornerstone of the first-line treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) since the CLEOPATRA trial. However, this long-standing paradigm is now being redefined by compelling evidence from practice-changing trials. Recent advances are challenging THP's dominance with impressive clinical activity across multiple trials evaluating anti-HER2 antibody-drug conjugates (ADC) and CDK4/6 inhibitors. The DESTINY-Breast09 (DB09) trial established superiority of the ADC trastuzumab deruxtecan (T-DXd) combined with pertuzumab over THP, positioning chemotherapy-free strategies as potential new standards. For patients with HR+/HER2+ disease, the PATINA study extends the first-line strategy by demonstrating that adding a CDK4/6 inhibitor as maintenance therapy significantly improves outcomes for patients with HR+/HER2+ disease who have completed initial THP induction. This review comprehensively summarizes the evolution of first-line treatment strategies for HER2+ mBC and critically evaluates clinical evidence from pivotal trials, including emerging evidence in first-line treatments and new agents with potential first-line applications. Challenges, including drug resistance mechanisms, optimal treatment sequencing, and management of special populations, are also discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMolecular Targeted TherapyAntibodies, Monoclonal, HumanizedNeoplasm MetastasisTrastuzumabTaxoidsProtein Kinase Inhibitors

Stichwörter der Autor:innen

HER2-positiveT-DXdTHPfirst-line therapymetastatic breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanpertuzumabAntibodies, Monoclonal, HumanizedTrastuzumabTaxoidsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • Dalian Medical University, Dalian, Liaoning, China.
  • Dalian University, Dalian, Liaoning, China. Electronic address: dlzhaozw@163.com.
  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Electronic address: man_li@dmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Dalian Medical University
  • Chinese Academy of Sciences
  • Dalian Institute of Chemical Physics, Chinese Academy of Sciences
  • Natural Science Foundation of Liaoning Province

Zitieren

APA

Zhang, L., Li, H., Sun, S., Li, N., Zhao, S., Zhao, Z., & Li, M. (2026). Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189649. https://doi.org/10.1016/j.bbcan.2026.189649

Vancouver

Zhang L, Li H, Sun S, Li N, Zhao S, Zhao Z, et al. Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189649. doi:10.1016/j.bbcan.2026.189649

BibTeX
@article{Zhang2026,
  author = {Zhang, Lanxin and Li, Huazhang and Sun, Siwen and Li, Ning and Zhao, Shanshan and Zhao, Zuowei and Li, Man},
  title = {Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  volume = {1881},
  number = {4},
  pages = {189649},
  doi = {10.1016/j.bbcan.2026.189649}
}
Kostenlos starten →